Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for RedHill Biopharma (RDHL) over the last 8 years, with Q2 2025 value amounting to $10.5 million.

  • RedHill Biopharma's Current Deferred Revenue fell 1534.01% to $10.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.5 million, marking a year-over-year decrease of 1534.01%. This contributed to the annual value of $9.3 million for FY2024, which is 1282.15% down from last year.
  • As of Q2 2025, RedHill Biopharma's Current Deferred Revenue stood at $10.5 million, which was down 1534.01% from $9.3 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Current Deferred Revenue ranged from a high of $47.9 million in Q4 2022 and a low of $9.3 million during Q4 2024
  • Over the past 5 years, RedHill Biopharma's median Current Deferred Revenue value was $26.0 million (recorded in 2021), while the average stood at $25.2 million.
  • As far as peak fluctuations go, RedHill Biopharma's Current Deferred Revenue soared by 6742.63% in 2021, and later tumbled by 7774.39% in 2023.
  • Over the past 5 years, RedHill Biopharma's Current Deferred Revenue (Quarter) stood at $30.7 million in 2021, then skyrocketed by 55.87% to $47.9 million in 2022, then tumbled by 77.74% to $10.7 million in 2023, then decreased by 12.82% to $9.3 million in 2024, then increased by 13.49% to $10.5 million in 2025.
  • Its Current Deferred Revenue stands at $10.5 million for Q2 2025, versus $9.3 million for Q4 2024 and $12.5 million for Q2 2024.